+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 110Years
All Genders
ID06168370

CT-Guided Personalized Antithrombotic Therapy Versus Lifelong Single Antiplatelet Therapy After Transcatheter Aortic Valve Implantation in Patients Without Atrial Fibrillation

Led by St. Antonius Hospital · Updated on 2026-05-19

2500

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a personalized approach to antithrombotic therapy compared to lifelong single antiplatelet therapy SAPT for patients who have undergone transcatheter aortic valve implantation TAVI and do not have a reason to take anticoagulants. The study aims to reduce the risk of blood clots and bleeding events, as the standard SAPT carries bleeding risks with only minimal protection against clots. The trial is pragmatic, international, and randomized, sponsored by St. Antonius Hospital. Participants in the experimental group will receive a CT scan three months after TAVI to check for valve thrombosis. If thrombosis is detected, they will begin anticoagulation treatment with apixaban, with doses adjusted based on specific criteria. If no thrombosis is found and there is no other reason to continue, SAPT will be stopped. The control group will continue standard care with lifelong SAPT. Treatment and monitoring will be guided by CT results. During the study, participants will be followed for about 2.5 years to track thromboembolic and bleeding events. Researchers will assess heart valve function annually using echocardiography and monitor quality of life with several questionnaires at baseline, 3, 12 months, and yearly thereafter. Medication adherence and cost-effectiveness of the CT-guided strategy will also be evaluated. The trial includes regular assessments to ensure safety and track outcomes over the median follow-up time.

CONDITIONS

Brief Title

Personalized, CT-guided Antithrombotic Therapy Versus Lifelong Single Antiplatelet Therapy to Reduce Thromboembolic and Bleeding Events in Non-atrial Fibrillation Patients After Transcatheter Aortic Valve Implantation

Research Team

C

Christiaan Overduin

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here